Agneta Siegbahn

List of Publications by Year
in descending order

89 papers	7,610 citations	94433 37 h-index	56724 83 g-index
94 all docs	94 docs citations	94 times ranked	14803 citing authors

#	Article	IF	Citations
1	Discovery and refinement of loci associated with lipid levels. Nature Genetics, 2013, 45, 1274-1283.	21.4	2,641
2	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet, The, 2016, 387, 2302-2311.	13.7	389
3	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. European Heart Journal, 2016, 37, 1582-1590.	2.2	329
4	Platelet-Derived Growth Factor is Angiogenic *In Vivo*. Growth Factors, 1992, 7, 261-266.	1.7	258
5	Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation. Circulation, 2014, 130, 1847-1858.	1.6	243
6	Large-scale Metabolomic Profiling Identifies Novel Biomarkers for Incident Coronary Heart Disease. PLoS Genetics, 2014, 10, e1004801.	3.5	225
7	Role of Platelet P-Selectin and CD40 Ligand in the Induction of Monocytic Tissue Factor Expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2322-2328.	2.4	217
8	Inflammatory Biomarkers Interleukin–6 and C–Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 4		
9	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. Journal of the American College of Cardiology, 2017, 70, 1760-1776.	2.8	140
10	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time. JAMA Cardiology, 2016, 1, 451.	6.1	137
11	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal, 2016, 37, 1325-1333.	2.2	137
12	High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. Journal of the American College of Cardiology, 2014, 63, 52-61.	2.8	133
13	GDF-15 for Prognostication of Cardiovascular and Cancer Morbidity and Mortality in Men. PLoS ONE, 2013, 8, e78797.	2.5	108
14	Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. Atherosclerosis, 2015, 242, 205-210.	0.8	108
15	Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. European Heart Journal, 2015, 36, 1901-1912.	2.2	107
16	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. European Heart Journal, 2018, 39, 1672-1686f.	2.2	106
17	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. American Heart Journal, 2015, 170, 1151-1160.	2.7	99
18	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clinical Chemistry, 2017, 63, 325-333.	3.2	97

#	Article	IF	Citations
19	Biomarker-Based Risk Model to PredictÂCardiovascular Mortality in PatientsÂWithÂStableÂCoronaryÂDisease. Journal of the American College of Cardiology, 2017, 70, 813-826.	2.8	95
20	Plasminogen Activator Inhibitor-1 Activity Is Independently Related to Both Insulin Sensitivity and Serum Triglycerides in 70-Year-Old Men. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 258-264.	2.4	94
21	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes and Endocrinology,the, 2017, 5, 534-543.	11.4	84
22	ProteinSeq: High-Performance Proteomic Analyses by Proximity Ligation and Next Generation Sequencing. PLoS ONE, 2011, 6, e25583.	2.5	80
23	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation, 2016, 134, 1697-1707.	1.6	76
24	Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip. Stroke, 2015, 46, 3340-3347.	2.0	71
25	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. PLoS Medicine, 2021, 18, e1003513.	8.4	70
26	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart, 2016, 102, 508-517.	2.9	67
27	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. Thrombosis and Haemostasis, 2020, 120, 538-564.	3.4	64
28	How to use D-dimer in acute cardiovascular care. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 69-80.	1.0	60
29	GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction. European Journal of Preventive Cardiology, 2017, 24, 1576-1583.	1.8	60
30	Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines. British Journal of Haematology, 1996, 95, 249-257.	2.5	49
31	A Unique Autophosphorylation Site in the Platelet-Derived Growth Factor alpha Receptor from a Heterodimeric Receptor Complex. FEBS Journal, 1994, 225, 29-41.	0.2	47
32	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart, 2014, 100, 1193-1200.	2.9	47
33	Platelet-Specific PDGFB Ablation Impairs Tumor Vessel Integrity and Promotes Metastasis. Cancer Research, 2020, 80, 3345-3358.	0.9	47
34	Lipoproteinâ€Associated Phospholipase A $_2$ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association, 2016, 5, .	3.7	44
35	Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. American Heart Journal, 2015, 169, 879-889.e7.	2.7	42
36	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. American Heart Journal, 2017, 190, 94-103.	2.7	42

#	ARTICLE	IF	CITATIONS
37	Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Human Molecular Genetics, 2016, 25, 1447-1456.	2.9	41
38	Regulation of chemotaxis by the cytoplasmic domain of tissue factor. Thrombosis and Haemostasis, 2005, 93, 27-34.	3.4	37
39	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. Clinical Chemistry, 2015, 61, 368-378.	3.2	37
40	D-dimer and factor VIIa in atrial fibrillation â€" prognostic values for cardiovascular events and effects of anticoagulation therapy. Thrombosis and Haemostasis, 2016, 115, 921-930.	3.4	34
41	Dabigatran etexilate and reduction in serum apolipoprotein B. Heart, 2016, 102, 57-62.	2.9	34
42	Cell Interactions with Collagen Matrices <i>In Vivo</i> and <i>In Vitro</i> Depend on Phosphatidylinositol 3-Kinase and Free Cytoplasmic Calcium. Cell Adhesion and Communication, 1998, 5, 461-473.	1.7	32
43	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. Journal of the American College of Cardiology, 2020, 75, 1145-1155.	2.8	28
44	Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. Journal of the American Heart Association, 2017, 6, .	3.7	27
45	Circulating cell-derived microparticles as biomarkers in cardiovascular disease. Biomarkers in Medicine, 2016, 10, 1009-1022.	1.4	26
46	C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2402-2410.	2.4	25
47	Tissue Factor Noncoagulant Signaling: Mechanisms and Implications for Cell Migration and Apoptosis. Seminars in Thrombosis and Hemostasis, 2015, 41, 691-699.	2.7	24
48	Proteomic Biomarkers for Incident Aortic Stenosis Requiring Valvular Replacement. Circulation, 2018, 138, 590-599.	1.6	24
49	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. International Journal of Cardiology, 2017, 245, 271-276.	1.7	22
50	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics, 2016, 17, 1425-1439.	1.3	21
51	Role of Extracellular Vesicles in Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2293-2309.	2.4	21
52	Genetic Landscape of the ACE2 Coronavirus Receptor. Circulation, 2022, 145, 1398-1411.	1.6	20
53	Pdgf-BB Triggered Cytoplasmic Calcium Responses in Cells with Endogenous or Stably Transfected PDGF β-Receptors. Growth Factors, 1995, 12, 191-201.	1.7	19
54	The Eph Tyrosine Kinase Receptors EphB2 and EphA2 Are Novel Proteolytic Substrates of Tissue Factor/Coagulation Factor VIIa. Journal of Biological Chemistry, 2014, 289, 32379-32391.	3.4	18

#	ARTICLE	IF	CITATIONS
55	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovascular Research, 2022, 118, 2112-2123.	3.8	18
56	Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. American Heart Journal, 2014, 168, 96-102.e2.	2.7	17
57	Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 500-510.	1.0	17
58	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. Journal of Thrombosis and Haemostasis, 2021, 19, 2726-2737.	3.8	17
59	Thrombin Generation During Cardiopulmonary Bypass Using Heparin-Coated or Standard Circuits. Scandinavian Journal of Thoracic and Cardiovascular Surgery, 1995, 29, 157-165.	0.2	16
60	High Plasma Levels of Heparin-Binding Epidermal Growth Factor Are Associated With a More Stable Plaque Phenotype and Reduced Incidence of Coronary Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 222-228.	2.4	15
61	The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients. Upsala Journal of Medical Sciences, 2017, 122, 224-233.	0.9	15
62	Extracellular vesicles in atrial fibrillation and stroke. Thrombosis Research, 2020, 193, 180-189.	1.7	15
63	The composition and daily variation of microparticles in whole blood in stable coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 25-32.	1.2	14
64	A Multi-Cohort Metabolomics Analysis Discloses Sphingomyelin (32:1) Levels to be Inversely Related to Incident Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104476.	1.6	14
65	Tissue factor/factor VIIa induces cell survival and gene transcription by transactivation of the insulin-like growth factor 1 receptor. Thrombosis and Haemostasis, 2014, 111, 748-760.	3.4	13
66	Identification of a Chemokinetic Inhibitor in Serum from Patients with Chronic Lymphocytic Leukaemia. Scandinavian Journal of Haematology, 1982, 28, 122-131.	0.0	12
67	Tissue factor/factor VIIa signalling promotes cytokine-induced beta cell death and impairs glucose-stimulated insulin secretion from human pancreatic islets. Diabetologia, 2015, 58, 2563-2572.	6.3	11
68	The chemokinetic inhibitory factor (CIF) in serum of CLL patients: Correlation with infection propensity and disease activity. Scandinavian Journal of Haematology, 1985, 35, 80-87.	0.0	9
69	Induction of differentiation in Uâ€937 and NB4 cells is associated with inhibition of tissue factor production. European Journal of Haematology, 1999, 63, 112-119.	2.2	9
70	Cross-talk between the Tissue Factor/coagulation factor VIIa complex and the tyrosine kinase receptor EphA2 in cancer. BMC Cancer, 2016, 16, 341.	2.6	9
71	Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy. Platelets, 2022, 33, 425-431.	2.3	9
72	Impact of physical activity on cardiovascular status in obesity. European Journal of Clinical Investigation, 2017, 47, 167-175.	3.4	8

#	Article	IF	Citations
73	Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient) Tj ETQq1 1 0.784314 rg BT /Overl	8.4	3
74	Activation of Î²1 integrins and caveolin-1 by TF/FVIIa promotes IGF-1R signaling and cell survival. Apoptosis: an International Journal on Programmed Cell Death, 2020, 25, 519-534.	4.9	8
75	Risk markers of incident atrial fibrillation in patients with coronary heart disease. American Heart Journal, 2021, 233, 92-101.	2.7	7
76	Cellular Origin of the Chemokinetic Inhibitor of Polymorphononuclear Leucocytes Found in Sera from Patients with Chronic Lymphocytic Leukaemia. Scandinavian Journal of Haematology, 1983, 31, 184-192.	0.0	6
77	Associations between circulating proteins and corresponding genes expressed in coronary thrombi in patients with acute myocardial infarction. Thrombosis Research, 2015, 136, 1240-1244.	1.7	6
78	Adipocytes express tissue factor and FVII and are procoagulant in a TF/FVIIa-dependent manner. Upsala Journal of Medical Sciences, 2019, 124, 158-167.	0.9	6
79	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. American Heart Journal, 2022, 251, 13-24.	2.7	6
80	Venous thrombosis: factor V G1691A genotyping related to APC resistance as measured by 2 methods. European Journal of Haematology, 1997, 58, 229-232.	2.2	5
81	Sensitive and Specific Detection of Platelet-Derived and Tissue Factorâ€"Positive Extracellular Vesicles in Plasma Using Solid-Phase Proximity Ligation Assay. TH Open, 2018, 02, e250-e260.	1.4	5
82	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis, 2020, 293, 35-41.	0.8	5
83	Specific binding of Bâ€CLL cellâ€derived chemokinetic inhibitory factor (CIF) to human polymorphonuclear leukocytes. European Journal of Haematology, 1987, 39, 172-179.	2.2	4
84	A stromal cell population in the large intestine identified by tissue factor expression that is lost during colorectal cancer progression. Thrombosis and Haemostasis, 2016, 116, 1050-1059.	3.4	3
85	The ABC risk score for patients with atrial fibrillation â€" Authors' reply. Lancet, The, 2016, 388, 1980-1981.	13.7	3
86	Carotid Endarterectomy Induces the Release of Inflammatory Markers and the Activation of Coagulation as Measured in the Jugular Bulb. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 2320-2328.	1.6	3
87	Response to Letter Regarding Article, â€œEfficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Tj ETQq1 1 0.784314 rg BT /Overlock 10		1
88	Tissue factor in ulcerative colitis, with and without concomitant primary sclerosing cholangitis. Upsala Journal of Medical Sciences, 2019, 124, 238-245.	0.9	1
89	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation: Response to Luo and Bu. Journal of Thrombosis and Haemostasis, 2022, 20, 537-537.	3.8	0